EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Botulinum Toxin-A, Generating a Hypothesis for Orofacial Pain Therapy

Yair Sharav, Rafael Benoliel, Yaron Haviv

Toxins · 2025

DOI: 10.3390/toxins17080389 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxins, 2025. Verfasst von Yair Sharav und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, Sedation and Imaging, Hadassah Medical Center, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem 911…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Facial Pain, Analgesics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orofacial pain encompasses a spectrum of disorders ranging from musculoskeletal disorders, such as myofascial pain, and temporomandibular disorders to neuropathic situations, such as trigeminal neuralgia and painful post-traumatic trigeminal neuropathy, and neurovascular pain such as orofacial migraine and cluster orofacial pain. Each require tailored prophylactic pharmacotherapy, such as carbamazepine, gabapentin, pregabalin, amitriptyline, metoprolol, and topiramate. Yet a substantial subset of patients remains refractory. Botulinum toxin type A (BoNT-A) has demonstrated growing efficacy in the treatment of multiple forms of orofacial pain, which covers the whole range of these disorders. We describe the analgesic properties of BoNT-A for each of the three following orofacial pain disorders: neuropathic, myofascial, and neurovascular. Then, we conclude with a section on the neuromodulatory mechanisms of BoNT-A. This lays the basis for the generation of a hypothesis for the segmental therapeutic action of BoNT-A on the whole range of orofacial pain disorders. In addition, the advantage of BoNT-A for providing a safe sustained effect after a single application for chronic pain prophylaxis is discussed, as opposed to the daily use of current conventional prophylactic medications. Finally, we summarize the clinical applications of BoNT-A for chronic orofacial pain therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AFacial PainAnalgesicsHumansAnimals

Stichwörter der Autor:innen

BoNT-Abotulinum toxinmigraineneuromodulationneuropathic painone-time pain prophylaxisorofacial paintemporomandibular disordertrigeminal neuralgia

Substanzen

Botulinum Toxins, Type AAnalgesics

Autor:innen und Institutionen

  • Department of Oral Medicine, Sedation and Imaging, Hadassah Medical Center, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
  • Rutgers School of Dental Medicine, Newark, NJ 07103, USA.

Zitieren

APA

Sharav, Y., Benoliel, R., & Haviv, Y. (2025). Botulinum Toxin-A, Generating a Hypothesis for Orofacial Pain Therapy. Toxins. https://doi.org/10.3390/toxins17080389

Vancouver

Sharav Y, Benoliel R, Haviv Y. Botulinum Toxin-A, Generating a Hypothesis for Orofacial Pain Therapy. Toxins. 2025. doi:10.3390/toxins17080389

BibTeX
@article{Sharav2025,
  author = {Sharav, Yair and Benoliel, Rafael and Haviv, Yaron},
  title = {Botulinum Toxin-A, Generating a Hypothesis for Orofacial Pain Therapy},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17080389}
}
Kostenlos starten →